A component of an enzyme family linked to DNA repair, stress responses, and cancer also plays a role in enhancing or inhibiting major cellular activities under physiological conditions, new research shows.
Researchers at UT Southwestern Medical Center, working with a California biotech firm, have developed a potential drug to treat polycystic kidney disease.
Scientists identify mechanisms behind harmful changes in the gut’s bacterial balance during inflammation
A study led by UT Southwestern Medical Center researchers has uncovered key molecular pathways behind the disruption of the gut’s delicate balance of bacteria during episodes of inflammatory disease.
UT Southwestern Medical Center researchers have identified an ion channel required for brain cells to suppress eating behavior in response to the hormone leptin or to the anti-obesity drug lorcaserin.
Cancer drug could double as a weapon against heart disease, promoting regeneration of damaged heart tissue
An anticancer agent in development promotes regeneration of damaged heart muscle – an unexpected research finding that may help prevent congestive heart failure in the future.
Biological differences that lead to variations in heart disease between men and women are far more complex than just differences in hormones. To address these differences, UT Southwestern Medical Center researchers say, standards need to be developed for treatment of heart disease in women.
UT Southwestern Medical Center researchers have identified a gene that protects the gut from inflammatory bowel disease (IBD).
UT Southwestern Medical Center research supports an evidence-based medicine (EBM) approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
The finding could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia. The stem cells die before they have an opportunity to transform into a blood cancer.
Scientists have found a way to inhibit the growth of glioblastoma, a type of brain cancer with low survival rates, by targeting a protein that drives growth of brain tumors, according to research from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center.